
IDYA Stock Forecast & Price Target
IDYA Analyst Ratings
Bulls say
IDEAYA Biosciences is positioned for success in the precision medicine oncology market due to its focus on integrating small molecule drug discovery with translational biomarker identification. With strong, consistent data from its clinical trials, including a statistically significant improvement in PFS and ORR, and demonstrated potential for real-world use, the company is likely to see accelerated approval for its lead program, darovasertib, in treating metastatic uveal melanoma. Additionally, the company has a strong pipeline of other development candidates and promising preclinical programs, further supporting its long-term growth potential. Investors should consider IDYA as a high-growth, developmental-stage biotech company, with a projected 10-year peak sales of $770M, and an estimated valuation of $58/share.
Bears say
IDEAYA Biosciences is an oncology-focused precision medicine company that faces challenges with the limited market opportunities in neo-adjuvant UM, and uncertainties around the commercialization of their pipeline programs. Key data metrics for IDYA's darovasertib are its 95% PoS for 1L metastatic UM and mPFS of 6.9 months, which, coupled with an early OS trend and favorable ORR and mDoR, drive our positive sentiment; however, we maintain a cautious outlook due to potential risks including disappointing PFS readouts, and limited market opportunity for HLA-A*02:01-negative mUM.
This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
IDYA Analyst Forecast & Price Prediction
Start investing in IDYA
Order type
Buy in
Order amount
Est. shares
0 shares